Natco Pharma seeks CDSCO emergency nod for Covid drug Molnupiravir
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
"The company is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients," Natco stated.
"Compassionate use" approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug. The company is ready to launch the product this month if approval is given.
Read also: Natco Pharma gets USFDA nod for Ibrutinib tablets in US
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
